Published in Eur J Nucl Med Mol Imaging on March 14, 2003
(99m)Tc-annexin V and (111)In-antimyosin antibody uptake in experimental myocardial infarction in rats. Eur J Nucl Med Mol Imaging (2005) 1.52
Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis. Proc Natl Acad Sci U S A (2013) 1.30
First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging (2006) 1.03
Imaging apoptosis in the eye. Eye (Lond) (2011) 0.96
Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models. Theranostics (2012) 0.95
Small-animal SPECT and SPECT/CT: application in cardiovascular research. Eur J Nucl Med Mol Imaging (2010) 0.93
Myocardial uptake of 99mTc-annexin-V and 111In-antimyosin-antibodies after ischemia-reperfusion in rats. Eur J Nucl Med Mol Imaging (2007) 0.90
Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications. J Cancer (2013) 0.85
A semi-automated technique for labeling and counting of apoptosing retinal cells. BMC Bioinformatics (2014) 0.85
Advances in radionuclide molecular imaging in myocardial biology. J Nucl Cardiol (2010) 0.83
Could 99mTc-glucarate be used to evaluate tumour necrosis? In vitro and in vivo studies in leukaemic tumour cell line U937. Eur J Nucl Med Mol Imaging (2008) 0.83
Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging. Theranostics (2013) 0.83
Current perspective of neuroprotection and glaucoma. Clin Ophthalmol (2015) 0.80
Discovery of Radioiodinated Monomeric Anthraquinones as a Novel Class of Necrosis Avid Agents for Early Imaging of Necrotic Myocardium. Sci Rep (2016) 0.79
New molecular imaging targets to characterize myocardial biology. Cardiol Clin (2009) 0.79
The feasibility of imaging myocardial ischemic/reperfusion injury using (99m)Tc-labeled duramycin in a porcine model. Nucl Med Biol (2014) 0.79
In vitro and in vivo evaluation of the influence of type III NaPi co-transporter activity during apoptosis on 99mTc-(V)DMSA uptake in the human leukaemic cell line U937. Eur J Nucl Med Mol Imaging (2004) 0.75
Radionuclide Imaging of Apoptosis in Malignancies: Promise and Pitfalls of Tc-Hynic-rh-Annexin V Imaging. Clin Med Oncol (2008) 0.75
Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol (2000) 16.47
Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med (1995) 10.91
Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med (2000) 9.52
Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood (1994) 9.10
A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature (2000) 6.12
Apoptotic pathways: paper wraps stone blunts scissors. Cell (2000) 4.37
Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood (1997) 4.01
Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet (2000) 3.71
Apoptotic pathways: the roads to ruin. Cell (1998) 3.44
In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A (1998) 2.39
Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med (2001) 2.26
A new method for radionuclide imaging of myocardial infarcts. Radiology (1974) 2.24
Electrocardiographic and clinical criteria for recognition of acute myocardial infarction based on analysis of 3,697 patients. Am J Cardiol (1983) 2.18
Brief report: recognition of acute myocarditis masquerading as acute myocardial infarction. N Engl J Med (1993) 2.14
Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med (1990) 1.92
Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med (2001) 1.91
Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms. J Am Coll Cardiol (2001) 1.67
Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood (1996) 1.64
Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol (1990) 1.55
Imaging cell death with radiolabeled annexin V in an experimental model of rheumatoid arthritis. J Nucl Med (2002) 1.54
Early postoperative reduction of monoclonal antimyosin antibody uptake is associated with absent rejection-related complications after heart transplantation. Circulation (1992) 1.52
Indium 111 antimyosin and Tc-99m glucaric acid for noninvasive identification of oncotic and apoptotic myocardial necrosis. J Nucl Cardiol (2002) 1.51
Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid. J Nucl Med (1991) 1.50
Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol (1999) 1.48
Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med (1993) 1.44
Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med (1990) 1.43
Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med (1999) 1.30
Detection and sizing of acute myocardial infarcts with 99mTc (Sn) tetracycline. N Engl J Med (1974) 1.28
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol (1984) 1.28
Measurement of phosphatidylserine exposure in leukocytes and platelets by whole-blood flow cytometry with annexin V. Blood Cells Mol Dis (2000) 1.20
Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-V in a mouse model. Circulation (2000) 1.18
The complexity of the phospholipid binding protein Annexin V. Thromb Haemost (1995) 1.17
Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in chinese hamster ovary cell cultures treated with cisplatin. Cytometry (1996) 1.16
Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine. Circ Res (1995) 1.11
Markers of apoptosis in cardiovascular tissues: focus on Annexin V. Cardiovasc Res (2000) 1.10
Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. Eur J Nucl Med (1999) 1.10
Active myocardial damage in hyperthyroidism. A concurrent mechanism of heart failure reversed by treatment. Eur Heart J (1995) 1.07
[99mTc]tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates. Bioconjug Chem (1996) 1.06
Imaging cyclophosphamide-induced intramedullary apoptosis in rats using 99mTc-radiolabeled annexin V. J Nucl Med (2001) 1.03
Specificity of localization of myosin-specific antibody fragments in experimental myocardial infarction. Histologic, histochemical, autoradiographic and scintigraphic studies. Circulation (1979) 1.02
Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi. Circulation (1995) 1.00
Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction. Clin Chim Acta (1996) 1.00
Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody. Circulation (1986) 0.98
Very early noninvasive detection of acute experimental nonreperfused myocardial infarction with 99mTc-labeled glucarate. Circulation (1997) 0.97
Monoclonal antibody to cardiac myosin: imaging of experimental myocardial infarction. Hybridoma (1984) 0.97
Radiolabeled annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation. Radiology (2000) 0.97
Prourokinase-annexin V chimeras. Construction, expression, and characterization of recombinant proteins. J Biol Chem (1995) 0.96
Myocardial injury: quantitation by cell sorting initiated with antimyosin fluorescent spheres. Science (1982) 0.96
Evaluation of annexin V as a platelet-directed thrombus targeting agent. Thromb Res (1994) 0.95
Acute myocardial infarct imaging with indium-111-labeled monoclonal antimyosin Fab. J Nucl Med (1987) 0.94
Detection of acute myocardial infarction by 99mTc-labeled D-glucaric acid imaging in patients with acute chest pain. J Nucl Med (1999) 0.92
Iodination of annexin V for imaging apoptosis. J Nucl Med (2002) 0.92
Indium-111 antimyosin scintigraphy to assess myocardial damage in patients with suspected myocarditis and cardiac rejection. J Nucl Med (1988) 0.92
Localization of radiolabeled cardiac myosin-specific antibody in myocardial infarcts. Comparison with technetium-99m stannous pyrophosphate. Circulation (1977) 0.92
Avidity of technetium 99m glucarate for the necrotic myocardium: in vivo and in vitro assessment. J Nucl Cardiol (1997) 0.91
Patient dosimetry of intravenously administered 99mTc-annexin V. J Nucl Med (2001) 0.89
Biodistribution and dosimetry of 99mTc-BTAP-annexin-V in humans. Eur J Nucl Med (2001) 0.89
99mTc annexin V imaging of neonatal hypoxic brain injury. Stroke (2000) 0.88
Noninvasive detection of human cardiac transplant rejection with indium-111 antimyosin (Fab) imaging. Circulation (1987) 0.87
The current role of infarct avid imaging. Semin Nucl Med (1999) 0.86
Technetium-99m glucarate uptake in a swine model of limited flow plus increased demand. J Nucl Cardiol (2000) 0.86
Annexins: calcium-binding proteins of multi-functional importance? Med Microbiol Immunol (1991) 0.85
Indium 111-monoclonal antimyosin antibody imaging in the diagnosis of acute myocarditis. Circulation (1987) 0.85
The use of technetium Tc 99m annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. J Thorac Cardiovasc Surg (1998) 0.85
Indium-111-monoclonal antimyosin antibody studies after the first year of heart transplantation. Identification of risk groups for developing rejection during long-term follow-up and clinical implications. Circulation (1990) 0.85
In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure. Cytometry (1997) 0.84
Myocardial damage does not occur in untreated hyperthyroidism unless associated with congestive heart failure. Am Heart J (1997) 0.83
Early imaging of experimental myocardial infarction by intracoronary administraion of 131I-labelled anticardiac myosin (Fab')2 fragments. Circulation (1978) 0.83
In vivo imaging of acute cardiac rejection in human patients using (99m)technetium labeled annexin V. Am J Transplant (2001) 0.81
99mTc-Hynic-annexin V imaging to evaluate inflammation and apoptosis in rats with autoimmune myocarditis. Eur J Nucl Med Mol Imaging (2002) 0.81
Antimyosin imaging in acute transmural myocardial infarctions: results of a multicenter clinical trial. J Am Coll Cardiol (1989) 0.81
Radionuclide imaging of acute lung transplant rejection with annexin V. Chest (2000) 0.81
99mTc-pyrophosphate imaging in patients with acute myocardial infarction: comparison of planar imaging with single-photon tomography with and without blood pool overlay. Circulation (1984) 0.81
Differentiation of myocardial ischemia and necrosis by technetium 99m glucaric acid kinetics. J Nucl Cardiol (1997) 0.80
In vivo detection of apoptotic cell death: a necessary measurement for evaluating therapy for myocarditis, ischemia, and heart failure. J Nucl Cardiol (1999) 0.80
Noninvasive diagnosis of cardiac allograft rejection. Another of many searches for the grail. Circulation (1992) 0.79
Radioimaging to identify myocardial cell death and probably injury. Lancet (2000) 0.79
Coronary endothelial dysfunction and myocardial cell damage in chronic stable idiopathic dilated cardiomyopathy. Int J Cardiol (2002) 0.79
Myocardial cell damage in human hypertension. J Am Coll Cardiol (2000) 0.79
Site-specific mutagenesis of annexin V: role of residues from Arg-200 to Lys-207 in phospholipid binding. Arch Biochem Biophys (1991) 0.79
Rapid infarct imaging with a technetium-99m-labeled antimyosin recombinant single-chain Fv: evaluation in a canine model of acute myocardial infarction. J Nucl Med (1993) 0.78
Myocardial scintigraphy with technetium-99m stannous pyrophosphate: an insensitive test for nontransmural myocardial infarction. Am J Cardiol (1979) 0.78
High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction. Nucl Med Commun (2002) 0.78
Active myocardial damage without attending inflammatory response in dilated cardiomyopathy. J Am Coll Cardiol (1993) 0.77
Annexin V counteracts apoptosis while inducing Ca(2+) influx in human lymphocytic T cells. Biochem Biophys Res Commun (1999) 0.77
Antimyosin uptake and myofibrillarlysis in dilated cardiomyopathy. J Nucl Cardiol (1998) 0.77
High prevalence of myocardial monoclonal antimyosin antibody uptake in patients with chronic idiopathic dilated cardiomyopathy. J Am Coll Cardiol (1989) 0.77
Burden of myocardial damage in cardiac allograft rejection: scintigraphic evidence of myocardial injury and histologic evidence of myocyte necrosis and apoptosis. J Nucl Cardiol (2000) 0.77
Evaluation of biopsy classification for rejection: relation to detection of myocardial damage by monoclonal antimyosin antibody imaging. J Am Coll Cardiol (1998) 0.77
Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies. Eur J Nucl Med (1991) 0.77
Noninvasive detection of cell death: from tracking epitaphs to counting coffins. J Nucl Cardiol (2002) 0.75
Dilated cardiomyopathy in HIV-infected patients. N Engl J Med (1999) 0.75
Indium-111-antimyosin antibody imaging for detecting different stages of myocardial infarction: comparison with technetium-99m-pyrophosphate imaging. J Nucl Med (1990) 0.75
Distribution of deoxyglucose and technetium-99m-glucarate in the acutely ischemic myocardium. J Nucl Med (1993) 0.75
Presence, evolving changes, and prognostic implications of myocardial damage detected in idiopathic and alcoholic dilated cardiomyopathy by 111In monoclonal antimyosin antibodies. Circulation (1994) 0.75
Frequency of myocardial indium-111 antimyosin uptake after uncomplicated coronary artery bypass grafting. Am J Cardiol (1990) 0.75
Assessment of myocardial damage in dilated-phase hypertrophic cardiomyopathy by using indium-111-antimyosin Fab myocardial scintigraphy. J Nucl Med (1991) 0.75
Technetium 99m glucarate: what will be its clinical role? J Nucl Cardiol (1997) 0.75
Evaluation of myocardial cell damage by In-111-monoclonal antimyosin antibodies in patients under chronic tricyclic antidepressant drug treatment. Circulation (1995) 0.75
Comparison of technetium-99m-glucarate and thallium-201 for the identification of acute myocardial infarction in rats. J Nucl Med (1992) 0.75
White paper of the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR) on multimodality imaging. Eur J Nucl Med Mol Imaging (2007) 4.75
Individual renal function based on 99mTc dimercaptosuccinic acid uptake corrected for renal size. Nucl Med Commun (2004) 2.01
Comparison of sulfur hexafluoride microbubble (SonoVue)-enhanced myocardial contrast echocardiography with gated single-photon emission computed tomography for detection of significant coronary artery disease: a large European multicenter study. J Am Coll Cardiol (2013) 1.58
Nuclear medicine, scientific publishing and the era of cost containment. Eur J Nucl Med Mol Imaging (2011) 1.50
Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: a prospective assessment. Int J Radiat Oncol Biol Phys (2004) 1.50
Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging (2010) 1.49
Reduced myocardial 18F-FDG uptake after calcium channel blocker administration. Initial observation for a potential new method to improve plaque detection. Eur J Nucl Med Mol Imaging (2011) 1.47
Expanding the scope of EJNMMI in the era of electronic publishing. Eur J Nucl Med Mol Imaging (2010) 1.39
Evolving myocardial infarction with ST elevation: anatomic considerations regarding the correlation between the site of occlusion and injured segments of the heart. Ann Noninvasive Electrocardiol (2004) 1.39
Of impact, metrics and ethics. Eur J Nucl Med Mol Imaging (2008) 1.14
Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl) (2006) 0.97
Recent developments in heart failure imaging. JACC Cardiovasc Imaging (2010) 0.93
Cardiac neurotransmission SPECT imaging. J Nucl Cardiol (2004) 0.90
Challenging the neuronal MIBG uptake by pharmacological intervention: effect of a single dose of oral amitriptyline on regional cardiac MIBG uptake. Eur J Nucl Med Mol Imaging (2004) 0.90
Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies. Cancer Treat Rev (2011) 0.87
Radionuclide imaging in heart failure: assessing etiology and outcomes and implications for management. J Nucl Cardiol (2002) 0.86
EJNMMI: the European way of communicating science. Eur J Nucl Med Mol Imaging (2013) 0.84
Targeting neuronal dysfunction and receptor imaging. Curr Opin Biotechnol (2007) 0.82
Density of striatal D2 receptors in untreated first-episode psychosis: an I123-IBZM SPECT study. Eur Neuropsychopharmacol (2011) 0.80
Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. Psychiatry Res (2006) 0.80
Coronary endothelial dysfunction and myocardial cell damage in chronic stable idiopathic dilated cardiomyopathy. Int J Cardiol (2002) 0.79
Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: an in vivo SPECT study. Schizophr Res (2011) 0.78
Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.77
Expanding indications for cardiac MIBG imaging of sympathetic activity. Eur J Nucl Med Mol Imaging (2011) 0.77
The current and future status of nuclear cardiology: a consensus report. Eur Heart J Cardiovasc Imaging (2014) 0.77
Use of electrical impedance tomography (EIT) for the assessment of unilateral pulmonary function. Physiol Meas (2002) 0.76
99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer. Eur J Nucl Med Mol Imaging (2004) 0.76
Key role of nuclear medicine in bringing imaging biomarkers into clinical practice. Eur J Nucl Med Mol Imaging (2009) 0.76
EANM-ESR white paper on multimodality imaging. Eur J Nucl Med Mol Imaging (2008) 0.75
Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. Neuroimage (2005) 0.75
Effects of therapy with amiodarone on clinical, functional, and cardiac sympathetic innervation in patients with idiopathic dilated cardiomyopathy. J Nucl Cardiol (2004) 0.75
Cardiac sympathetic imaging with mIBG: a tool for better assessment of the diabetic heart. Eur J Nucl Med Mol Imaging (2010) 0.75
Radionuclide noninvasive evaluation of heart failure beyond left ventricular function assessment. J Nucl Cardiol (2009) 0.75
Is cardiac autonomic neuropathy the basis of nonischemic diabetic cardiomyopathy? JACC Cardiovasc Imaging (2010) 0.75
The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study. Psychiatry Res (2012) 0.75
On cloning research, peer review and the possibility of fraud. Eur J Nucl Med Mol Imaging (2006) 0.75
Molecular imaging in animal models of disease--every little detail counts! Eur J Nucl Med Mol Imaging (2005) 0.75
Deriving global quantitative tumor response parameters from 18F-FDG PET-CT scans in patients with non-Hodgkin's lymphoma. Nucl Med Commun (2015) 0.75
For whom the bell tolls. Eur J Nucl Med Mol Imaging (2008) 0.75
Value of radionuclide studies in cardiac transplantation. Ann Nucl Med (2006) 0.75
Left ventricular end-diastolic volume is decreased at maximal exercise in athletes with marked repolarisation abnormalities: a continuous radionuclide monitoring study. Eur J Nucl Med Mol Imaging (2004) 0.75